Announcements Trials

Browse Landscape

Phase

Phase 2 4 Phase 1 4 Phase 1/2 1

Status

Sponsor Class

Study Type

Interventional 1

Sponsor

Cancer Type

Genitourinary 2 Thoracic 1 Dermatologic 1

Conditions

Neoplasms 1 Melanoma 1

Interventions

pembrolizumab 81 Nivolumab 55 Ipilimumab 44 Cyclophosphamide 38 aldesleukin 26 Interleukin-2 25 fludarabine 17 Temozolomide 17 fludarabine phosphate 16 trametinib 11 dabrafenib 11 Radiotherapy 11 Biopsy 11 avelumab 10 Paclitaxel 9 spartalizumab 8 cemiplimab 8 Dacarbazine 8 Cisplatin 8 Bevacizumab 8 sargramostim 7 binimetinib 7 Fluorouracil 7 poly ICLC 6 lenvatinib 6 epacadostat 6 atezolizumab 6 Magnetic Resonance Spectroscopy 6 Granulocyte-Macrophage Colony-Stimulating Factor 6 montanide ISA 51 5

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

Clinical Trials

1 trials

Recent Start date Enrollment

Phase 1/2 × Protein Subunit Vaccines × Dermatologic × Clear all

NCT02126579 2024-02-28

MEL60

University of Virginia

Phase 1/2 Completed

50 enrolled 13 charts

Melanoma, Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon ⚡